Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Interaction of AFQ056 with Cocaine in Cocaine Use Disorder
NCT04771143Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in cocaine use disorder (CUD) comparing AFQ056 with Placebo (2 arms). Primary endpoint: Number of Participants with Treatment Emergent Adverse Events at Day 40. Planned start Jul 2021; status: withdrawn.
02
Drugs
mavoglurant
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT04771143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771143.